High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.

@article{Stackelberg2008HighdoseCW,
  title={High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.},
  author={Arend von Stackelberg and Reinhard Hartmann and Christoph A B{\"u}hrer and Ruediger Fengler and Gritta E. Janka-Schaub and A. Reiter and Georg Mann and Kjeld Schmiegelow and Richard Ratei and Thomas Klingebiel and Joerg Ritter and G{\"u}nter H R Henze},
  journal={Blood},
  year={2008},
  volume={111 5},
  pages={2573-80}
}
High-dose methotrexate (MTX) has been extensively used for treatment of acute lymphoblastic leukemia (ALL). To determine the optimal dose of MTX in childhood relapsed ALL, the ALL Relapse Berlin-Frankfurt-Münster (ALL-REZ BFM) Study Group performed this prospective randomized study. A total of 269 children with a first early/late isolated (n = 156) or combined (n = 68) bone marrow or any isolated extramedullary relapse (n = 45) of precursor B-cell (PBC) ALL (excluding very early marrow relapse… CONTINUE READING